Important information has been given by the Central Government in the Delhi High Court regarding the vaccine of Zydus Cadila. The Central government in its affidavit filed in the Delhi High Court on Friday said that the test for the age group 12 to 18 is nearing completion. At the same time, the Delhi High Court said that let the trials of the vaccine be completed, it would be dangerous if children are vaccinated without thorough trials. Please tell that this vaccine is to be given to the age group of 12-18 years.
Dr. NK Arora, chairman of the Kovid Working Group, had said recently that the trial of Zydus Cadila's vaccine is almost complete. Children 12 to 18 years old can start planting it by the end of July or in August. He had also said that in the coming times, our target is to administer one crore vaccine doses daily.
Dr. NK Arora had also said that according to an ICMR study, the third wave is likely to be late. In such a situation, we still have time to vaccinate everyone in the country. In such a situation, in the coming days, our target is to give 1 crore doses every day.
Earlier, in a petition filed in the Supreme Court, the central government had said in an affidavit regarding the status of vaccine availability that Zydus Cadila, which is developing the DNA vaccine, has completed clinical trials on the age group of 12 to 18 years and it will get statutory approval. After this vaccine may be available for 12 to 18-year-olds in the near future.
Significantly, a petition has been filed in the Delhi High Court regarding the vaccine trial on children of 12 to 18 years. It states that the trial of the Kovid vaccine on this age group is tantamount to genocide and should be stopped immediately. The Drug Controller General of India (DCGI) has approved Bharat Biotech for trials on children of Covaxin.
Petitioner Sanjeev Kumar said that this application is before the High Court. In this notice has also been sent to the Center and Bharat Biotech. Despite this, vaccine trials have been started on children since June.